scholarly journals Correction to: Functional Connectivity in Adult Brain Tumor Patients: A Systematic Review, by Fox ME and King TZ. Brain Connect 2018;8(7):381–397. DOI: 10.1089/brain.2018.0623

2018 ◽  
Vol 8 (9) ◽  
pp. 577-577
Keyword(s):  
Systematic Review ◽  
Brain Tumor ◽  
Functional Connectivity ◽  
Adult Brain ◽  
Tumor Patients

Rehabilitation pathways in adult brain tumor patients in the first 12 months of disease. A retrospective analysis of services utilization in 719 patients

2016 ◽  
Vol 24 (11) ◽  
pp. 4801-4806 ◽  
Author(s):  
Andrea Pace ◽  
Veronica Villani ◽  
Cristiano Parisi ◽  
Stefano Di Felice ◽  
Margaux Lamaro ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Retrospective Analysis ◽  
Adult Brain ◽  
Tumor Patients ◽  
Services Utilization

Commentary: Post-Acute Cognitive Rehabilitation for Adult Brain Tumor Patients

Neurosurgery ◽  
2021 ◽  
Author(s):  
Viktoria Sefcikova ◽  
Gerry Christofi ◽  
George Samandouras
Keyword(s):  
Brain Tumor ◽  
Cognitive Rehabilitation ◽  
Adult Brain ◽  
Tumor Patients

scholarly journals Brain tumors and COVID-19: the patient and caregiver experience*

2020 ◽  
Vol 2 (1) ◽  
Author(s):  
Mathew R Voisin ◽  
Kathy Oliver ◽  
Stuart Farrimond ◽  
Tess Chee ◽  
Jean Arzbaecher ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Task Force ◽  
Quality Care ◽  
Healthcare Providers ◽  
Global Scale ◽  
Adult Brain ◽  
Sources Of Information ◽  
Long Term Effects ◽  
Tumor Patients ◽  
Care Information

Abstract Background Since the COVID-19 pandemic began, thousands of medical procedures and appointments have been canceled or delayed. The long-term effects of these drastic measures on brain tumor patients and caregivers are unknown. The purpose of this study is to better understand how COVID-19 has affected this vulnerable population on a global scale. Methods An online 79-question survey was developed by the International Brain Tumour Alliance, in conjunction with the SNO COVID-19 Task Force. The survey was sent to more than 120 brain tumor charities and not-for-profits worldwide and disseminated to pediatric and adult brain tumor patients and caregivers. Responses were collected from April to May 2020 and subdivided by patient versus caregiver and by geographical region. Results In total, 1989 participants completed the survey from 33 countries, including 1459 patients and 530 caregivers. There were no significant differences in COVID-19 testing rates (P = .662) or positive cases for brain tumor patients between regions (P = .1068). Caregivers were significantly more anxious than patients (P ≤ .0001). Patients from the Americas were most likely to have lost their jobs due to the pandemic, practiced self-isolation, and received telehealth services (P ≤ .0001). Patients from Europe experienced the most treatment delays (P = .0031). Healthcare providers, brain tumor charities, and not-for-profits were ranked as the most trusted sources of information. Conclusions As a result of COVID-19, brain tumor patients and caregivers have experienced significant stress and anxiety. We must continue to provide accessible high-quality care, information, and support in the age of COVID-19.

scholarly journals P05.01 the efficacy of donepezil on cognitive function in postoperative brain tumor patients

2019 ◽  
Vol 21 (Supplement_3) ◽  
pp. iii33-iii34
Author(s):  
Y Diansari ◽  
Y Harun ◽  
S Marisdina ◽  
Y Felistia
Keyword(s):  
Cognitive Impairment ◽  
Brain Tumor ◽  
Cognitive Function ◽  
Acetylcholinesterase Inhibitor ◽  
Primary Brain Tumor ◽  
Adult Brain ◽  
Cognitive Domain ◽  
Cognitive Test ◽  
Tumor Patients ◽  
Old Patients

Abstract BACKGROUND Cognitive impairment is frequently found in brain tumor patients. More than 90% of patients with brain tumor have at least one cognitive domain disturbance. Decline in cognitive function could happen before due to the tumor or after the treatment because of surgery, radiotherapy or chemotherapy. Until now there is no available standard treatment for patients with cognitive impairment due to brain tumor. Moreover, Donepezil is an acetylcholinesterase inhibitor known to be useful for improving cognitive function in patients with dementia. This clinical study aims to determine the cognitive effects of donepezil therapy in patients with brain tumors following surgery. MATERIAL AND METHODS This is a pilot study with total of 20 adult brain tumor patients were double blinded randomly assigned to receive a single daily dose (5mg for 12 weeks) of donepezil or placebo. The inclusion criteria were patients with primary brain tumor who had undergone surgery with cognitive impairment at the initial evaluation and age range 18 to 65 years old. Patients with previous cognitive problem, other diseases that can cause cognitive decline e.g. stroke and history of taking donepezil, memantine, methylphenidate, ginkgo biloba, and modafinil were excluded. A cognitive test using Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment Indonesia Version (MoCA-INA) assessing memory, attention, language, visuospatial, verbal fluency, and executive functions were administered before random assignment and at 4, 8 and 12 weeks. A cognitive composite score (primary outcome) and individual cognitive domains were evaluated. Furthermore, side effects and adverse events were also recorded. RESULTS Of this mostly middle-age (30–60 years old), female, meningioma as primary brain tumor with frontal and temporal lobe are the most frequent locations. After 12 weeks of treatment, the composite scores did differ significantly between groups (MMSE P=0.027, MoCA-INA P=0.024). Furthermore, the significant differences favouring donepezil were observed for orientation and recall domains using MMSE with p value 0.017 and 0.006 respectively. Visuospatial (P=0.034) and delayed recall domains (P=0.004) were significant through MoCA-INA evaluation. In addition, Mean MMSE score for pre-donepezil administration was 14.60 ± 4.47 and after 3 months was 20.40 ± 4.24 (P=0.000). Mean MoCA-INA score for pre-donepezil administration was 9.30 ± 3.65 and after 3 months was 15.30 ± 4.24 (P=0.000). However, there was no differences in the placebo group (MMSE P= 0.066, MoCA-INA P=0.313). CONCLUSION Three months treatment with donepezil significantly improve the cognitive functions among post-operative brain tumor patients with no reported side effect. Moreover, further research is needed for longer duration of follow-up and possibility of increased doses.

Sign in / Sign up

Export Citation Format

Share Document